Sunshine Biopharma EBIT per Share
The EBIT per Share of Sunshine Biopharma (SBFM) as of Oct 31, 2026 is -9.13 USD. In the previous year, EBIT per Share was -2.25 USD — a change of 305.26% (lower).
Get this data via API
Financial Data API
EBIT per Share
-9.13USD
YoY
305.26%
Last updated:
The Sunshine Biopharma EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.00USD | -100.00% |
| est | 3.53USD | -138.72% |
| -9.13USD | +305.26% | |
| -2.25USD | -99.94% | |
| -3,987.75USD | +103,735.58% | |
| -3.84USD | -43.58% | |
| -6.81USD | +104.36% | |
| -3.33USD | +18,234.33% | |
| -0.02USD | -93.39% | |
| -0.27USD | -39.91% | |
| -0.46USD | +432.60% | |
| -0.09USD | -100.00% | |
| -3,901.38USD | -77.77% | |
| -17,551.14USD | -9.35% | |
| -19,360.77USD | +173.97% | |
| -7,066.80USD | +27.05% | |
| -5,562.02USD | +4,138.70% | |
| -131.22USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sunshine Biopharma Stock analysis
Frequently Asked Questions about Sunshine Biopharma stock
EBIT per Share of Sunshine Biopharma is -9.13 USD in 2025.
EBIT per Share of Sunshine Biopharma changed from -2.25 USD to -9.13 USD, representing a 305.26% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Sunshine Biopharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Sunshine Biopharma
All Key Metrics — Sunshine Biopharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth